ClearPoint Neuro, Inc. (CLPT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CLPT Revenue Growth
Revenue Breakdown (FY 2025)
CLPT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CLPT Revenue Analysis (2014–2025)
As of May 8, 2026, ClearPoint Neuro, Inc. (CLPT) generated trailing twelve-month (TTM) revenue of $37.0 million, reflecting explosive growth of +34.0% year-over-year. The most recent quarter (Q4 2025) recorded $10.4 million in revenue, up 17.5% sequentially.
Looking at the longer-term picture, CLPT's 5-year compound annual growth rate (CAGR) stands at +23.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $37.0 million in 2025, representing a new all-time high.
Revenue diversification analysis shows CLPT's business is primarily driven by Biologics and Drug Delivery Revenue (58%), Biologics and Drug Delivery - Disposable Products (23%), and Capital Equipment and Software Revenue (10%). With over half of revenue concentrated in Biologics and Drug Delivery Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVCR (+8.5% YoY), INVA (+13.6% YoY), and ABT (+6.4% YoY), CLPT has outperformed the peer group in terms of revenue growth. Compare CLPT vs NVCR →
CLPT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CLPTCurrent | $37M | +34.0% | +23.6% | -65.4% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 ABT | $42.0B | +6.4% | +5.6% | 16.3% | |
 MDT | $33.5B | +6.9% | +3.0% | 17.8% | |
 ANGO | $292M | +7.3% | +2.1% | -13.7% |
CLPT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $37.0M | +17.8% | $22.7M | 61.4% | $-24,164,000 | -65.4% |
| 2024 | $31.4M | +31.0% | $19.1M | 60.9% | $-19,746,000 | -62.9% |
| 2023 | $24.0M | +16.6% | $13.6M | 56.8% | $-22,446,000 | -93.7% |
| 2022 | $20.6M | +26.1% | $13.5M | 65.8% | $-16,332,000 | -79.5% |
| 2021 | $16.3M | +27.0% | $11.1M | 68.2% | $-13,374,000 | -82.1% |
| 2020 | $12.8M | +14.4% | $9.1M | 71.1% | $-6,220,000 | -48.5% |
| 2019 | $11.2M | +52.5% | $7.3M | 64.9% | $-4,594,000 | -41.0% |
| 2018 | $7.4M | -0.4% | $4.9M | 66.9% | $-5,247,768 | -71.4% |
| 2017 | $7.4M | +28.4% | $4.5M | 60.7% | $-6,335,837 | -85.9% |
| 2016 | $5.7M | +25.1% | $3.1M | 54.0% | $-7,488,738 | -130.3% |
See CLPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCLPT — Frequently Asked Questions
Quick answers to the most common questions about buying CLPT stock.
Is CLPT's revenue growth accelerating or slowing?
CLPT revenue is accelerating at +34.0% year-over-year, exceeding the 5-year CAGR of +23.6%. TTM revenue reached $37M. Growth momentum has increased versus prior periods.
What is CLPT's long-term revenue growth rate?
ClearPoint Neuro, Inc.'s 5-year revenue CAGR of +23.6% reflects the sustained expansion pattern. Current YoY growth of +34.0% is above this long-term average.
How is CLPT's revenue distributed by segment?
CLPT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.